|
Vaccine |
Brand Name |
Manufacturer |
Thimerosal Concentration1 |
Mercury |
Date Approved or Changed |
pg in 2001 PDR |
|
Anthrax |
Anthrax vaccine |
BioPort Corporation |
0 |
0 |
||
|
DTaP |
Acel-Imune Tripedia |
Wyeth-Ayerst Aventis Pasteur |
.01% * |
25 --* |
no
longer produced |
1653
|
|
DTwP |
All Products |
.01% |
25 |
|||
|
DT |
All Products |
.01% |
25 |
|||
|
Td |
All Products |
.01% |
25 |
|||
|
TT |
All Products |
.01% |
25 |
|||
|
DTwP-Hib |
Tetramune |
Wyeth-Ayerst |
.01% |
25 |
no
longer produced |
|
|
Hib |
ActHIB/Omni HIB |
Aventis Pasteur |
0 |
0 |
09-27-96 |
767 |
|
Hepatitis A |
Havrix |
GlaxoSmithKline |
0 |
0 |
|
3094 |
|
Hepatitis B |
Engerix-B preservative
free |
GlaxoSmithKline Merck |
.005% .005% |
12.5 12.5 |
03-28-00 |
3087 |
|
Hep A-B |
Twinrix |
GlaxoSmithKline |
0 |
0 |
05-11-2001 |
|
|
Influenza |
All products in U.S. |
.01% |
25 |
|||
|
IPV |
IPOL |
Aventis Pasteur |
0 |
0 |
778 |
|
|
Lyme |
LYMErix |
GlaxoSmithKline |
0 |
0 |
12-21-98 |
3108 |
|
Meningococcal |
Menomune A, C, AC and A/C/Y/W-135 |
Aventis Pasteur |
783 |
|||
|
MMR |
MMR-II |
Merck |
0 |
0 |
1952 |
|
|
Measles |
Attenuvax |
Merck |
0 |
0 |
1882 |
|
|
OPV |
Orimune |
Wyeth-Ayerst |
0 |
0 |
no
longer produced |
|
|
Pneumococcal |
Prevnar |
Wyeth-Ayerst |
0 |
0 |
02-17-00 |
1673 |
|
Rabies |
Rabies Vaccine Adsorbed |
Bioport Corporation |
.01% |
25 |
03-18-88 |
|
|
Rotavirus |
Rotashield |
Wyeth-Ayerst |
0 |
0 |
08-31-98 withdrawn 10-15-99 |
|
|
Typhoid |
Vivotef Berna |
Berna |
0 |
0 |
04-97 (PDR) |
933 |
|
Typhoid Fever |
Typhim Vi |
Aventis Pasteur |
0 |
0 |
06-95 (PDR) 02-09-94 (PDR) |
794 3467 |
|
Varicella |
Varivax |
Merck |
0 |
0 |
03-17-95 |
2038 |
|
Yellow Fever
|
YF-Vax |
Aventis Pasteur |
0 |
0 |
05-96 (PDR) |
796 |
___ - shaded text indicates vaccines no longer in production
1. A concentration of 1:10,000
is equivalent to a 0.01% concentration. Thimerosal is approximately 50% Hg by
weight. A 1:10,000 concentration contains 25 micrograms of Hg per
0.5 mL.
2. A previously marketed lyophilized preparation contained 0.05%
thimerosal.
3. COMVAX is not approved for use under 6 weeks of age because
of decreased response to the Hib component.
* This product should be considered
equivalent to thimerosal-free products. This vaccine may contain trace
amounts (<0.3 mcg) of mercury left after post-production thimerosal removal;
these amounts have no biological effect. JAMA 1999;282(18) and JAMA
2000;283(16).
Information provided by http://www.vaccinesafety.edu/thi-table.htm